Plasma aldosterone and its relationships with left ventricular mass in essential hypertensive patients with the metabolic syndrome

American Journal of Hypertension

Volumn 21, Issue 9, 2008, Pages 1055-1061

  Mulè, Giuseppe ^a   Nardi, Emilio ^a   Cusimano, Paola ^a   Cottone, Santina ^a   Seddio, Giovanna ^a   Geraci, Calogero ^a   Palermo, Alessandro ^a   Andronico, Giuseppe ^a   Cerasola, Giovanni ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CAUCASIAN; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; OBESITY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL;

ADULT; ALDOSTERONE; BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; METABOLIC SYNDROME X; RENIN;

EID: 50249172188     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2008.225     Document Type: Article

References (38)

1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol 2006; 21:1-6.
2. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, Mannarino E. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004; 43:1817-1822.
3. Andreadis EA, Tsourous GI, Tzavara CK, Georgiopoulos DX, Katsanou PM, Marakomichelakis GE, Diamantopoulos EJ. Metabolic syndrome and incident cardiovascular morbidity and mortality in a Mediterranean hypertensive population. Am J Hypertens 2007; 20:558-564.
4. Pierdomenico SD, Lapenna D, Di Tommaso R, Di Carlo S, Caldarella MP, Neri M, Mezzetti A, Cuccurullo F. Prognostic relevance of metabolic syndrome in hypertensive patients at low-to-medium risk. Am J Hypertens 2007; 20:1291-1296.
5. Mulè G, Cerasola G. The metabolic syndrome and its relationship to hypertensive target organ damage. J Clin Hypertens (Greenwich) 2006; 8:195-201.
6. Mulè G, Nardi E, Cottone S, Cusimano P, Volpe V, Piazza G, Mongiovi R, Mezzatesta G, Andronico G, Cerasola G. Influence of metabolic syndrome on hypertension-related target organ damage. J Intern Med 2005; 257:503-513.
7. Mulè G, Cottone S, Mongiovì R, Cusimano P, Mezzatesta G, Seddio G, Volpe V, Nardi E, Andronico G, Piazza G, Cerasola G. Influence of metabolic syndrome on aortic stiffness in never treated hypertensive patients. Nutr Metab Cardiovasc Dis 2006; 16:54-59.
8. Ingelsson E, Sullivan LM, Murabito JM, Fox CS, Benjamin EJ, Polak JF, Meigs JB, Keyes MJ, O'Donnell CJ, Wang TJ, D'Agostino RB Sr, Wolf PA, Vasan RS. Prevalence and prognostic impact of subclinical cardiovascular disease in individuals with the metabolic syndrome and diabetes. Diabetes 2007; 56:1718-1726.
9. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond) 2007; 113:267-278.
10. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F; PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48:2293-2300.
11. Sealey JE, Campbell GA, Preibisz JJ. Hormone assays: renin, aldosterone, peripheral vein, renal vein and urinary assays. Guidelines to methodology and interpretation. In Laragh JH, Brenner BM (eds), Hypertension: Pathophysiology, Diagnosis and Management. Raven Press: New York, 1990, 1443-1460.
12. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 2001; 14:603-609.
13. Sahn DJ, DeMaria A, Kisslo J, Weiman A. The Committee on M-mode standardization of the American Society of Echocardiography. Circulation 1978; 58:1072-1073.
14. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-458.
15. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and of their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995; 25:1056-1062.
16. El-Gharbawy AH, Nadig VS, Kotchen JM, Grim CE, Sagar KB, Kaldunski M, Hamet P, Pausova Z, Gaudet D, Gossard F, Kotchen TA. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension 2001; 37:845-850.
17. Egan BM, Stepniakowski K, Goodfriend TL. Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering. Am J Hypertens 1994; 7:886-893.
18. Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F, Shamlaye C, Burnier M. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006; 48:239-245.
19. Kidambi S, Kotchen JM, Grim CE, Raff H, Mao J, Singh RJ, Kotchen TA. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 2007; 49:704-711.
20. Egan BM, Papademetriou V, Wofford M, Calhoun D, Fernandes J, Riehle JE, Nesbitt S, Michelson E, Julius S. Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. Am J Hypertens 2005; 18:3-12.
21. Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, Jacques PF, Fox CS, Meigs JB, Levy D, Larson MG, Selhub J, D'Agostino RB Sr, Wang TJ, Vasan RS. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 2007; 116:984-992.
22. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201-207.
23. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res 1998; 24:789-796.
24. Rocchini AP, Katch VL, Grekin R, Moorehead C, Anderson J. Role for aldosterone in blood pressure regulation of obese adolescents. Am J Cardiol 1986; 57:613-618.
25. Andronico G, Cottone S, Mangano MT, Ferraro-Mortellaro R, Baiardi G, Grassi N, Ferrara L, Mulè G, Cerasola G. Insulin, renin-aldosterone system and blood pressure in obese people. Int J Obes Relat Metab Disord 2001; 25: 239-242.
26. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 2004; 43:358-363.
27. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, Hauner H, McCann SM, Scherbaum WA, Bornstein SR. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Nat Acad Sci USA 2003; 100:14211-14216.
28. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 2007; 115:1345-1353.
29. Petrasek D, Jensen G, Tuck M, Stern N. In vitro effects of insulin on aldosterone production in rat zona glomerulosa cells. Life Sci 1992; 50:1781-1787.
30. Goodfriend TL, Egan B, Steptniakowski K, Ball DL. Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension 1995; 25:30-36.
31. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 2007; 30:2349-2354.
32. Calle C, Campiòn J, Garcìa-Arencibia M, Maestro B, Dàvila N. Transcriptional inhibition of the human insulin receptor gene by aldosterone. J Steroid Biochem Mol Biol 2003; 84:543-553.
33. Shigematsu Y, Hamada M, Okayama H, Hara Y, Hayashi Y, Kodama K, Kohara K, Hiwada K. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension 1997; 29:723-727.
34. Schmieder RE, Messerli FH, Garavaglia GE, Nunez B, MacPhee AA, Re RN. Does the renin-angiotensin-aldosterone system modify cardiac structure and function in essential hypertension? Am J Med 1988; 84:136-139.
35. Duprez DA, Bauwens FR, De Buyzere ML, De Backer TL, Kaufman JM, Van Hoecke J, Vermeulen A, Clement DL. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1993; 71:17A-20A.
36. Schroeder AP, Sihm I, Morn B, Thygesen K, Pedersen EB, Lederballe O. Influence of humoral and neurohormonal factors on cardiovascular hypertrophy in untreated essential hypertensives. Am J Hypertens 1996; 9:207-215.
37. Malmqvist K, Ohman KP, Lind L, Nystrom F, Kahan T. Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin. J Intern Med 2002; 252:430-439.
38. Vasan RS, Evans JC, Benjamin EJ, Levy D, Larson MG, Sundstrom J, Murabito JM, Sam F, Colucci WS, Wilson PWF. Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart study. Hypertension 2004; 43:957-962.